Clinical Trial Update: DETERMINE Trial Treatment Arm 03: Entrectinib in Adult, Paediatric and Teenage/Young Adult Patients With ROS1 Gene Fusion-Positive Cancers. [Phase 2, Phase 3]

View source ↗

Summary

This clinical trial update describes Arm 03 of the DETERMINE trial evaluating entrectinib in adults, pediatric, and teenage/young adult patients with ROS1 gene …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Brain Neoplasms
• Glioma
• Melanoma
• Solid Tumors

Drugs mentioned

• Rozlytrek (entrectinib)

Snippet

Sponsor: Cancer Research UK | Conditions: Haematological Malignancy, Malignancy | Phase 2, Phase 3 | Status: RECRUITING